ABEO vs. IMUX, RZLT, CLRB, ADAG, FGEN, CRVS, CTXR, PMVP, RLMD, and ACET
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Immunic (IMUX), Rezolute (RZLT), Cellectar Biosciences (CLRB), Adagene (ADAG), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
Abeona Therapeutics' return on equity of -161.82% beat Immunic's return on equity.
Immunic currently has a consensus price target of $8.50, indicating a potential upside of 582.73%. Abeona Therapeutics has a consensus price target of $21.00, indicating a potential upside of 377.27%. Given Abeona Therapeutics' higher probable upside, research analysts plainly believe Immunic is more favorable than Abeona Therapeutics.
Abeona Therapeutics has higher revenue and earnings than Immunic. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics received 420 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.31% of users gave Abeona Therapeutics an outperform vote while only 65.73% of users gave Immunic an outperform vote.
51.8% of Immunic shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Immunic has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
In the previous week, Abeona Therapeutics had 6 more articles in the media than Immunic. MarketBeat recorded 10 mentions for Abeona Therapeutics and 4 mentions for Immunic. Immunic's average media sentiment score of -0.15 beat Abeona Therapeutics' score of -0.36 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
Summary
Abeona Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
